Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Biofrontera Inc. | Ameluz (BF-200 ALA) | Basal cell carcinoma | Phase 3 | Enrollment Conclusion | Topical | Oncology |
| Biofrontera Inc. | Ameluz (BF-200 ALA) | Actinic Keratosis | Phase 3 | Topical | N/A | |
| Biogen Inc. | Felzartamab - (TRANSCEND) | Antibody-mediated rejection (AMR) in kidney transplant recipients | Phase 3 | Ongoing | Intravenous | Immunosuppressant |
| Biogen Inc. | LEQEMBI IQLIK (lecanemab-irmb)(at-home injection) | Early Alzheimer's disease (AD) a-home injection | PDUFA | Ongoing | Subcutaneous injection | Neurology |
| Biogen Inc. | BIIB091 | Multiple Sclerosis (MS) | Phase 2 | Enrollment Initiation | Oral | Neurology |
| Biogen Inc. | Bardoxolone methyl - CATALYST | Pulmonary arterial hypertension associated with connective tissue disease - CTD-PAH | Phase 3 | Trial Discontinued | Oral | Cardiology |
| Biogen Inc. | Felzartamab (MOR202) - (PROMINENT) | Membranous nephropathy (MN) | Phase 3 | Enrollment Initiation | Intravenous | Immunology |
| Biogen Inc. | Bardoxolone - (FALCON) | Chronic Kidney Disease | Phase 3 | Trial Discontinued | Oral | N/A |
